EP3571292A1 - Conditionally immortalized cells and methods for their preparation - Google Patents
Conditionally immortalized cells and methods for their preparationInfo
- Publication number
- EP3571292A1 EP3571292A1 EP18707762.3A EP18707762A EP3571292A1 EP 3571292 A1 EP3571292 A1 EP 3571292A1 EP 18707762 A EP18707762 A EP 18707762A EP 3571292 A1 EP3571292 A1 EP 3571292A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- promoter
- cells
- iacmcs
- dox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 126
- 239000013598 vector Substances 0.000 claims abstract description 87
- 230000001939 inductive effect Effects 0.000 claims abstract description 47
- 108091027981 Response element Proteins 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 437
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 76
- 210000001519 tissue Anatomy 0.000 claims description 41
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 35
- 210000002064 heart cell Anatomy 0.000 claims description 34
- 238000013518 transcription Methods 0.000 claims description 34
- 230000035897 transcription Effects 0.000 claims description 34
- 238000012258 culturing Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 210000005033 mesothelial cell Anatomy 0.000 claims description 12
- 210000001054 cardiac fibroblast Anatomy 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 7
- 102100025169 Max-binding protein MNT Human genes 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 210000003699 striated muscle Anatomy 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 108091006107 transcriptional repressors Proteins 0.000 claims description 5
- 230000000754 repressing effect Effects 0.000 claims description 4
- 101710128836 Large T antigen Proteins 0.000 claims 1
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 94
- 230000014509 gene expression Effects 0.000 description 79
- 230000003287 optical effect Effects 0.000 description 40
- 230000000747 cardiac effect Effects 0.000 description 35
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 31
- 230000002062 proliferating effect Effects 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- -1 Apocl/2/3/4 Proteins 0.000 description 30
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 29
- 230000001746 atrial effect Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000013507 mapping Methods 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 28
- 241000282414 Homo sapiens Species 0.000 description 27
- 230000001625 cardiomyogenic effect Effects 0.000 description 27
- 239000002609 medium Substances 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 24
- 239000001963 growth medium Substances 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000000638 stimulation Effects 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 238000011529 RT qPCR Methods 0.000 description 14
- 210000002072 atrial myocyte Anatomy 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 210000002837 heart atrium Anatomy 0.000 description 11
- 210000005003 heart tissue Anatomy 0.000 description 11
- 238000012744 immunostaining Methods 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 101710107217 Tertiapin Proteins 0.000 description 10
- 230000009815 adipogenic differentiation Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 102000001045 Connexin 43 Human genes 0.000 description 9
- 108010069241 Connexin 43 Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 8
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 229920006184 cellulose methylcellulose Polymers 0.000 description 8
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 210000002235 sarcomere Anatomy 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 108010091086 Recombinases Proteins 0.000 description 7
- 102000018120 Recombinases Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000011153 ceramic matrix composite Substances 0.000 description 7
- 238000003501 co-culture Methods 0.000 description 7
- 230000032459 dedifferentiation Effects 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 238000002073 fluorescence micrograph Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 206010003658 Atrial Fibrillation Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 6
- 210000000818 brown preadipocyte Anatomy 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 101150024821 tetO gene Proteins 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 101150009118 Atp2a2 gene Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 101150051809 KCNH2 gene Proteins 0.000 description 5
- 108010054278 Lac Repressors Proteins 0.000 description 5
- 101150050438 NPPA gene Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 229960004754 astemizole Drugs 0.000 description 5
- 238000000098 azimuthal photoelectron diffraction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000003855 cell nucleus Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 108700004025 env Genes Proteins 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000002570 interstitial cell Anatomy 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- 238000004264 monolayer culture Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000000449 purkinje cell Anatomy 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 description 4
- OOBJCYKITXPCNS-REWPJTCUSA-N (3s)-5-(2,6-difluorophenoxy)-3-[[(2s)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-4-oxopentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)COC1=C(F)C=CC=C1F OOBJCYKITXPCNS-REWPJTCUSA-N 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 4
- 102000005606 Activins Human genes 0.000 description 4
- 108010078606 Adipokines Proteins 0.000 description 4
- 102000014777 Adipokines Human genes 0.000 description 4
- 239000012109 Alexa Fluor 568 Substances 0.000 description 4
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 4
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 4
- 102100035882 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- 108050009340 Endothelin Proteins 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 101150012075 Kcnj3 gene Proteins 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 101150107698 MYH6 gene Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- 101150042605 RYR2 gene Proteins 0.000 description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 108010031318 Vitronectin Proteins 0.000 description 4
- 102100035140 Vitronectin Human genes 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 230000004156 Wnt signaling pathway Effects 0.000 description 4
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 4
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 239000000488 activin Substances 0.000 description 4
- 239000000478 adipokine Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 229960002756 azacitidine Drugs 0.000 description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 description 4
- 210000001593 brown adipocyte Anatomy 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 229960003603 decitabine Drugs 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 4
- 229950000234 emricasan Drugs 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 4
- 229960001596 famotidine Drugs 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000010382 gamma-tocopherol Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 4
- 239000003688 hormone derivative Substances 0.000 description 4
- 229960002474 hydralazine Drugs 0.000 description 4
- 101150026234 iam gene Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 210000005246 left atrium Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 108700007229 noggin Proteins 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229960001802 phenylephrine Drugs 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 229920000768 polyamine Polymers 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 4
- 230000002336 repolarization Effects 0.000 description 4
- 235000021283 resveratrol Nutrition 0.000 description 4
- 229940016667 resveratrol Drugs 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 210000002363 skeletal muscle cell Anatomy 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000003408 sphingolipids Chemical class 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000005495 thyroid hormone Substances 0.000 description 4
- 229940036555 thyroid hormone Drugs 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 229960000604 valproic acid Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000002478 γ-tocopherol Substances 0.000 description 4
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 4
- 229940124225 Adrenoreceptor agonist Drugs 0.000 description 3
- 102100021590 Bcl-2-like protein 10 Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 101000685824 Homo sapiens Probable RNA polymerase II nuclear localization protein SLC7A6OS Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 101150043413 MYH7 gene Proteins 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 102100023136 Probable RNA polymerase II nuclear localization protein SLC7A6OS Human genes 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 108010034634 Repressor Proteins Proteins 0.000 description 3
- 102000009661 Repressor Proteins Human genes 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 101150013356 TNNT2 gene Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000000555 contractile cell Anatomy 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- ZGSXEXBYLJIOGF-BOPNQXPFSA-N iwr-1 Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=O)C(C=C1)=CC=C1N1C(=O)[C@@H]2C(C=C3)CC3[C@@H]2C1=O ZGSXEXBYLJIOGF-BOPNQXPFSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 3
- 210000005167 vascular cell Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- CFPWPNDPUSLDPF-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]-2-phosphonoacetic acid Chemical compound NC(=N)N(C)C(C(O)=O)P(O)(O)=O CFPWPNDPUSLDPF-UHFFFAOYSA-N 0.000 description 2
- 241000242764 Aequorea victoria Species 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101150095166 CACNA1C gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 101100332765 Homo sapiens EEF1A1 gene Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 101150098715 KCND3 gene Proteins 0.000 description 2
- 101150068759 KCNJ2 gene Proteins 0.000 description 2
- 101150107475 MEF2C gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000747945 Marchantia polymorpha Uncharacterized mitochondrial protein ymf34 Proteins 0.000 description 2
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 2
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000014413 Neuregulin Human genes 0.000 description 2
- 108050003475 Neuregulin Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 101150114527 Nkx2-5 gene Proteins 0.000 description 2
- 101000768120 Oryza nivara Uncharacterized protein ycf76 Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 101150059087 Scn5a gene Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000044409 human EEF1A1 Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910012375 magnesium hydride Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000025687 phenotypic switching Effects 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 210000004043 pneumocyte Anatomy 0.000 description 2
- 210000000557 podocyte Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000036390 resting membrane potential Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000000518 sarcolemma Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000004929 transmission Raman spectroscopy Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- FKJMFCOMZYPWCO-HNNXBMFYSA-N (3s)-5-(2,6-dichlorobenzoyl)oxy-4-oxo-3-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound N([C@@H](CC(=O)O)C(=O)COC(=O)C=1C(=CC=CC=1Cl)Cl)C(=O)OCC1=CC=CC=C1 FKJMFCOMZYPWCO-HNNXBMFYSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- HAPJROQJVSPKCJ-UHFFFAOYSA-N 3-[4-[2-[6-(dibutylamino)naphthalen-2-yl]ethenyl]pyridin-1-ium-1-yl]propane-1-sulfonate Chemical compound C1=CC2=CC(N(CCCC)CCCC)=CC=C2C=C1C=CC1=CC=[N+](CCCS([O-])(=O)=O)C=C1 HAPJROQJVSPKCJ-UHFFFAOYSA-N 0.000 description 1
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 102100023961 ADP-ribosylation factor-like protein 2-binding protein Human genes 0.000 description 1
- 101150067539 AMBP gene Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102100021177 ATP-sensitive inward rectifier potassium channel 11 Human genes 0.000 description 1
- 229940126565 ATP-synthase inhibitor Drugs 0.000 description 1
- 101000818108 Acholeplasma phage L2 Uncharacterized 81.3 kDa protein Proteins 0.000 description 1
- 101150020966 Acta2 gene Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108700008960 Adenovirus E3-6.7K Proteins 0.000 description 1
- 101900054233 African swine fever virus Apoptosis regulator Bcl-2 homolog Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 101150102415 Apob gene Proteins 0.000 description 1
- 101150094024 Apod gene Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101710181273 Apoptosis regulator Bcl-2 homolog Proteins 0.000 description 1
- 108010084085 Atrial Myosins Proteins 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 101150010153 BARF1 gene Proteins 0.000 description 1
- 101150032367 BIRC8 gene Proteins 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 108700032588 Baculovirus p35 Proteins 0.000 description 1
- 101150067964 BcRF1 gene Proteins 0.000 description 1
- 101710121492 Bcl-2-like protein 10 Proteins 0.000 description 1
- 101001027553 Bos taurus Fibronectin Proteins 0.000 description 1
- 101150112512 CBX7 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101150069920 Camk2a gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000520666 Carmotetraviridae Species 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 229940121709 Cytochrome C oxidoreductase inhibitor Drugs 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000615461 Dicistroviridae Species 0.000 description 1
- 101001044938 Dictyostelium discoideum Diacylglycerol kinase A Proteins 0.000 description 1
- 101150118728 Dlx5 gene Proteins 0.000 description 1
- 101100452644 Drosophila melanogaster Ilp2 gene Proteins 0.000 description 1
- 101150075174 E1B gene Proteins 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 101150049876 EDN1 gene Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 101710120810 Elongation factor 1-alpha 1 Proteins 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101900034680 Epstein-Barr virus Apoptosis regulator BHRF1 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 101150018889 FABP4 gene Proteins 0.000 description 1
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 101150048336 Flt1 gene Proteins 0.000 description 1
- 101900157622 Fowlpox virus Apoptosis regulator Bcl-2 homolog Proteins 0.000 description 1
- 101150057182 GFAP gene Proteins 0.000 description 1
- 101150036925 HCN4 gene Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 101710094895 HTLV-1 basic zipper factor Proteins 0.000 description 1
- 101000912350 Haemophilus phage HP1 (strain HP1c1) DNA N-6-adenine-methyltransferase Proteins 0.000 description 1
- 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 description 1
- 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108700002729 Herpesvirus saimiri STP Proteins 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 description 1
- 101000614701 Homo sapiens ATP-sensitive inward rectifier potassium channel 11 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101100272581 Homo sapiens BIRC7 gene Proteins 0.000 description 1
- 101000934823 Homo sapiens Barttin Proteins 0.000 description 1
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 1
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000764260 Homo sapiens Troponin T, cardiac muscle Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 101000805434 Human herpesvirus 8 type P (isolate GK18) viral cyclin homolog Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000073062 Iflaviridae Species 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 241001505307 Jembrana disease virus Species 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- 101150051253 KCNJ5 gene Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 101150090219 Kcnj11 gene Proteins 0.000 description 1
- 101150088608 Kdr gene Proteins 0.000 description 1
- 102100040487 Keratin, type I cytoskeletal 13 Human genes 0.000 description 1
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 1
- 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
- 101000790844 Klebsiella pneumoniae Uncharacterized 24.8 kDa protein in cps region Proteins 0.000 description 1
- 101150002998 LCAT gene Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101150074995 MYL2 gene Proteins 0.000 description 1
- 101150069582 MYL4 gene Proteins 0.000 description 1
- 101150040007 MYLK gene Proteins 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000579048 Merkel cell polyomavirus Species 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100001652 Mus musculus Amy2 gene Proteins 0.000 description 1
- 101100226589 Mus musculus Fabp1 gene Proteins 0.000 description 1
- 101100452019 Mus musculus Icam2 gene Proteins 0.000 description 1
- 101100477823 Mus musculus Smtn gene Proteins 0.000 description 1
- 101150054386 Myh11 gene Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 108700018807 Myxoma virus M11L Proteins 0.000 description 1
- 101150031207 NOS3 gene Proteins 0.000 description 1
- 101800001014 Non-structural protein 5A Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
- 108010053291 Oncogene Protein v-akt Proteins 0.000 description 1
- 108010078627 Oncogene Protein v-crk Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 101000783504 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 15.4 kDa protein Proteins 0.000 description 1
- 101150117945 PDGFB gene Proteins 0.000 description 1
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 description 1
- 241000057726 Panine gammaherpesvirus 1 Species 0.000 description 1
- 241001526370 Papiine gammaherpesvirus 1 Species 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 1
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241001631648 Polyomaviridae Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 101150027249 RL1 gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101100383168 Rattus norvegicus Cdkn2b gene Proteins 0.000 description 1
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150113054 SELE gene Proteins 0.000 description 1
- 101150001462 SFTPB gene Proteins 0.000 description 1
- 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 1
- 101710142113 Serine protease inhibitor A3K Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 101150069872 Slc5a2 gene Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101150104529 Stmn2 gene Proteins 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 101150101626 TAGLN gene Proteins 0.000 description 1
- 101150020577 TNNI3 gene Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000710915 Totiviridae Species 0.000 description 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101150085237 UL36 gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 101710101493 Viral myc transforming protein Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 101710086987 X protein Proteins 0.000 description 1
- 101100049199 Xenopus laevis vegt-a gene Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 210000002309 caveolated cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000000238 cell of claudius Anatomy 0.000 description 1
- 210000000354 cell of hensen Anatomy 0.000 description 1
- 210000001431 cementocyte Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 101150109673 dbh gene Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000001968 dental pulp cell Anatomy 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- IKALZAKZWHFNIC-UHFFFAOYSA-L dipotassium;2-aminobutanedioate Chemical compound [K+].[K+].[O-]C(=O)C(N)CC([O-])=O IKALZAKZWHFNIC-UHFFFAOYSA-L 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 101150104041 eno2 gene Proteins 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 101150003286 gata4 gene Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000001173 gonocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000037183 heart physiology Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 101150032953 ins1 gene Proteins 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001074 muscle attachment cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 101150105254 nkx-2.5 gene Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000001915 nurse cell Anatomy 0.000 description 1
- 210000002560 odontocyte Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000000414 pleural mesothelial cell Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 230000003649 pro-hypertrophic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940041030 streptogramins Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003444 urethra cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002395 vitreous cell Anatomy 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
Definitions
- the invention relates to methods for reversible immortalization of cells, cells and cell lines obtained with such methods and vectors and kits of parts used in such methods.
- parenchymal/fully differentiated cells of human origin Proliferation and (terminal) differentiation are mutually exclusive processes in most cell lineages. Accordingly, differentiated mammalian cells usually cannot be expanded ex vivo, which severely limits in vitro studies of especially (parenchymal) cells derived from hard-to-obtain (healthy) tissues ⁇ e.g. human brain, lung, heart, kidney, liver).
- One way to obtain large numbers of cells from small tissue samples is by immortalizing the cells directly after their isolation from tissue samples followed by their ex vivo expansion in a dedifferentiated state and their
- PSC-CMCs pluripotent stem cells
- Immortalization of mammalian primary cells is typically accomplished by endowing them with viral or non-viral genes encoding proteins that trigger cell division and telomere synthesis (also referred to as immortalization genes).
- these immortalization genes have been flanked, with recombinase recognition sites to allow their excision following cell amplification thereby facilitating the subsequent redifferentiation of the cells.
- recombinase-mediated excision process is never complete, there will always be some cells that have retained the immortalization gene(s) present in the resulting cell population. These cells will gradually "overgrow" the deimmortalized cells.
- Cardiomyocyte lines have been generated using cardiac muscle cells from rodents and humans as starting material and the simian virus 40 (SV40) large T (LT) antigen to induce cell proliferation (Steinhelper et al, 1990; Jahn et al, 1996; Claycomb et al, 1998; Rybkin et al, 2003; Davidson el al, 2005; Goldman et al, 2006; Zhang et al, 2009).
- SV40 simian virus 40
- LT large T
- Cre-LoxP site-specific recombination system to genera te lines of conditionally immortalized neonatal rat ventricular myocytes. Cre-mediated removal of the LT expression module and exposure to cardiomyogenic differentiation conditions did, however, not give rise to excitable or contractile cells.
- immortalization gene is flanked with recombinase recognition sites to allow its excision following cell amplification thereby facilitating redifferentiation of the cells has some inherent disadvantages. Firstly, immortalization and subsequent deimmortalization of the cells requires two consecutive genetic manipulations. Secondly, due to the specific nature of the recombinase-mediated excision reaction, repeated switching between proliferative and differentiated cell states is impractical making deimmortalization essentially an irreversible process. Thirdly, recombinase-mediated excision reactions are never complete. Consequently, after recombinase treatment of a cell population, there will always be a fraction of cells that has retained the immortalization gene.
- the present invention aims to overcome the drawbacks of currently existing immortalization methods and/or the poor differentiation capacity of deimmortalized cell lines generated by currently existing methods for
- the invention therefore provides a vector comprising: - a promoter sequence
- the promoter is preferably a cell type- or tissue-specific promoter and/or a promoter that is active in a differentiated form of said cell, more preferably a cell type-specific promoter.
- the invention further provides a genetically modified eukaryotic cell provided with a vector, said vector comprising:
- the invention provides a cell line comprising a plurality of cells according to the invention.
- the invention provides a kit of parts comprising a cell or cell line according to the invention and an agent capable of activating or repressing said inducible promoter.
- the invention provides a method for generating one or more conditionally immortalized cells, the method comprising introducing one or more vectors according to the invention into one or more eukaryotic cells resulting in one or more genetically modified eukaryotic cells.
- the present inventors have developed a novel method for conditionally and reversibly immortalizing and subsequently ⁇ differentiating cells. It was surprisingly found that with this method conditionally immortalized
- cardiomyocytes spontaneously and synchronously underwent full cardiomyogenic differentiation following shutdown of immortalization factor production giving rise to cells that very closely resembled the primary cardiomyocytes from which they were derived without the use of complex or expensive cocktails of dLifferentiation factors. Both the extent, i.e. the percentage and the quality, i.e. the
- the reversibly immortalized cells of the present invention have great potential as models for both fundamental and applied cardiac research and provide easy-to-use and cost-effective alternatives for PSC-derived differentiated cells.
- the obtained cells outperform all existing lines of cardiac muscle cells in terms of cardiomyogenic differentiation ability.
- the invention therefore provides a vector comprising:
- Such vector is herein also referred to as a vector according to the invention.
- the term "vector” refers to a nucleic acid molecule used, as a vehicle to introduce nucleic acid sequences into a eukaryotic cell.
- the nucleic can be DNA or RNA.
- the vector according to the invention is a DNA molecule.
- Introduction of a vector into a eukaryotic cell yields a genetically modified cell.
- Vectors known to the art that can be used in the present invention include viral vectors and free nucleic acids, such as plasmids or nucleic acid. fragments.
- the vector according to the invention is a viral vector or a plasmid, more preferably a viral vector.
- Viral vectors useful in invention include those based on Retroviridae including alpharetro-, betaretro-, deltaretro-, epsilonretro-, gammaretro-, lenti- and spumaviruses, Parvoviridae, Hepadnaviridae, Herpesviridae (e.g.
- Epstein-Barr virus and human herpesvirus 6 Epstein-Barr virus and human herpesvirus 6
- Papilloma viridae e.g. SV40 and Merkel cell polyomavirus
- Adenoviridae e.g. Baculoviridae, Circoviridae and Poxviridae
- the viral vector is preferably a replication-defective viral vector such as an integration-competent lentiviral vector.
- Suitable viral vectors can be obtained from, amongst others, human immunodeficiency virus (HTV), simian immunodeficiency virus (STY), equine infectious anemia virus (EIAV), bovine immune deficiency virus (BIV), caprine arthritis encephalitis virus (CAEV), visna virus, Jembrana disease virus (JOY) and feline immunodeficiency virus (FTV).
- HTV human immunodeficiency virus
- STY simian immunodeficiency virus
- EIAV equine infectious anemia virus
- BIV bovine immune deficiency virus
- CAEV caprine arthritis encephalitis virus
- visna virus Jembrana disease virus
- JOY Jembrana disease virus
- FTV feline immunodeficiency virus
- the vector is a non-viral integration-competent vector based on transposases, integrases or nucleases together with an appropriate template for transposition, integration and homologous recombin
- a vector according to the invention may further comprise other elements such as long terminal repeats (LTRs), trans-activation response (TAR) elements, primer activation signals (PASs), primer binding sites (PBSs), packaging signals, Rev-responsive elements (RREs), constitutive transport elements (CTEs), RNA transport elements (RTEs), central termination sequences (CTSs), central polypimne tracts (cPPTs), polypurine tracts (PPTs), posttranscriptional regulatory elements of e.g.
- LTRs long terminal repeats
- TAR trans-activation response
- PASs primer activation signals
- PBSs primer binding sites
- RREs Rev-responsive elements
- CTEs constitutive transport elements
- RTEs RNA transport elements
- CTSs central termination sequences
- cPPTs central polypimne tracts
- PPTs polypurine tracts
- HVBPRE human hepatitis B virus
- WHVPRE woodchuck hepatitis virus
- IRSs internal ribosome entry sites
- 2A peptide(-Iike) sequences recognition and coding sequences for small drug-regulated repressor proteins like the tetracycline (Tc)-controlled hybrid protein rtTR-KRAB and the CymR repressor.
- the LTRs contain repetitive sequences important for the transcription (e.g. TAR elements), reverse transcription (e.g. PASs) and host chromosomal DNA integration of retroviral genomes.
- Reverse transcription of retrovirus genomes in general further depends on PBSs and PPTs, while the reverse transcription of lentivirus and lentiviral vector genomes also requires CTSs and cPFrs.
- the CTSs and cPPTs also play a role in the nuclear import of reverse transcribed lentiviral genomes.
- Packaging signal direct the incorporation of retrovirus genomes into viral particles.
- the RREs are important for the efficient nucleocytoplasmic export of lentivir us and lentiviral vector-encoded unspliced and incompletely spliced.
- CTEs and RTEs have similar effects.
- genes delivered by retroviral vectors can be inefficient.
- the posttranscriptional regulatory elements of Hepadnaviridae and the RREs, CTEs and RTEs of Retroviridae might help resolve this problem. Insertion of such elements in the untranslated regions (UTRs) of the coding sequences of a lentiviral or other retroviral vector may increase their expression level.
- IRES internal ribosome entry site
- mRNA messenger RNA
- IRESs are commonly located in the 5' UTR of positive-stranded RNA viruses with uncapped genomes.
- Another means to express 2 proteins from a single mRNA molecule is by insertion of a 2A peptide(-like) sequence in between their coding sequence. 2A peptide(-like) sequences mediate self-processing of primary translation products by a process variously referred to as "ribosome skipping", "stop-go” translation and "stop carry-on” translation.
- 2A peptide(-like) sequences are present in various groups of positive- and double-stranded RNA viruses including Picornaviridae, Iflaviridae, Tetraviridae, Dicistroviridae, Reoviridae and Totiviridae.
- rtTR-KRAB binds to Tet operator (tetO) sequences in the absence, but not in the presence, of a Tc class antibiotic. Binding of rtTR-KRAB to tetO sequences in the vicinity of promoters inhibits transcription. After binding to a Tc class antibiotic, rtTtR-KRAB undergoes a conformational change strongly weakening its interaction with -tetO sequences thereby allowing transcriptional activation of a. nearby promoter. CymR binds to the cumate operator site (CuO), which, when inserted immediately downstream of a promoter blocks transcription originating from this promoter. Addition of cumate, a small, non-toxic molecule, relieves the repression.
- CuO cumate operator site
- promoter sequence refers to a region of a nucleic acid sequence that is essential for the initiation of transcription of a nucleic acid sequence of interest. Transcription regulatory factors can bind to a promoter sequence.
- the promoter is a cell type- or tissue-specific promoter and/or a promoter that is active in a differentiated form of the eukaryotic cell. Any promoter that is active in the differentiated form of the type of cell that is to be provided with the vector can be used. Hence, in a preferred embodiment, the promoter is a promoter that is active in the differentiated form of the eukaryotic cell.
- the activity of a promoter that is active in a differentiated form of the eukaryotic cell in the context of the present invention is preferably not significantly less active and preferably not active in a less differentiated progenitor of said eukaryotic cell.
- Significantly less active is preferably a level of activity of the promoter that is at most 50% of the level, more preferably at most 30% of the level and more preferably at most 10% of the level in the differentiated cell.
- the level of activity is preferably measured by measuring the level of mRNA produced from the promoter in the untransformed cell and comparing the level in a differentiated form of said cell with the level in an undifferentiated form of the same cell, or a different but otherwise comparable untransformed cell.
- a differentiated form of a cell or a differentiated cell refers to a cell that is more specialized in its fate or function than at a previous stage in the cell's development.
- a cell progresses from an uncommitted cell type, such as a PSC, typically via lineage- restricted precursor cells, to a specific differentiated cell type.
- the term includes both cells that are terminally differentiated and cells that are not (yet) terminally differentiated but are more specialized than at a previous stage in their
- a differentiated form of a cell is thus a cell with a mature phenotype specific for a. particular tissue or organ system.
- A. "proliferative form" of a cell refers to a cell undergoing mitosis. Typically, in a. normal tissue proliferative forms of a cell are not yet terminally differentiated cells.
- a proliferative phenotype is induced by expressing one or more immortalization genes in a. cell, which can be a differentiated cell isolated from a tissue of interest.
- immortalization and thus the establishment of a proliferative phenotype, is reversible.
- a promoter that is active in a differentiated form of the cell would be intrinsically more active following cell differentiation than before, whereas in the methods of the invention transcription of the gene that is controlled by the promoter should be inhibited.
- the present inventors found that the use of a promoter that is active in a differentiated form of the eukaryotic cell actually leads to a better result, i.e. the advantages of the present invention include the production of cells that very closely resemble the primary differentiated cells from which they were derived prior to immortalization, the synchronicity of the differentiation process and/or the high percentage of differentiated cells that are obtained.
- tissue-specific promoter refers to a promoter that initiates expression of the gene of interest essentially only in certain tissues.
- tissue-specific promoter initiates expression essentially only in cardiac tissue.
- cell type-specific promoter refers to a promoter that initiates expression of the gene of interest essentially only in a specific cell type or only in a specific cell type in a particular tissue, although it may also initiate expression of the gene in another cell type in another tissue.
- a cardiomyocyte-specific promoter initiates expression essentially only in
- cardiomyocytes or only in cardiomyocytes as the only cell type in cardiac tissue As the only cell type in cardiac tissue.
- the MHCK7 promoter (Salva et al. 2007) initiates expression both in cardiomyocytes and in skeletal muscle cells. But, since skeletal muscle cells are not present in cardiac tissue, such cells cannot be immortalized in a cardiac tissue sample and the MHCK.7 is suitable for use in the present invention. If the promoter is a tissue-specific promoter, it is preferred that the eukaryotic cell is a cell derived from the same tissue.
- said tissue is cardiac tissue
- said eukaryotic cell is a cardiac cell, such as a cardiac fibroblast, a cardiomyocyte, an epicardial mesothelial cell or any other cardiac cell type like a nodal cell or a cardiac Purkinje cell
- said promoter is a cardiac tissue-specific promoter.
- cardiac tissue-specific promoter refers to a promoter that initiates substantially higher levels of transcription in cardiac cells, such as cardiac fibroblasts, cardiomyocytes and epicardial mesothelial cells than in non-cardiac tissue cells. If the promoter is a cell type-specific promoter, it is preferred that the eukaryotic cell is a cell of the same type for which the promoter is specific.
- said cell for which the promoter is specific and said eukaryotic cell are a cardiac cell, such as a cardiac fibroblast, a cardiomyocyte, an epicardial mesothelial cell or any other cardiac cell type like a nodal cell or a. cardiac Purkinje cell.
- the promoter is a cell type-specific promoter.
- a promoter is cardiac cell type- or tissue-specific if the transcription levels induced by the promoter in cardiac cells are at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 50-fold, 100-fold, 500-fold or 1000-fold higher or more as compared to the transcription levels initiated by the promoter in other tissues.
- the promoter is a tissue-specific promoter
- the eukaryotic cell is a primary cell derived from the same tissue and the promoter is active in a differentiated form of said cell.
- the promoter is a cardiac cell-specific promoter, such as a cardiac fibroblast-specific promoter, a cardiomyocyte-specific promoter, an epicardial mesothelial cell -specific promoter, a nodal cell-specific promoter or a cardiac Purkinje cell-specific promoter
- the eukaryotic cell is a primary cardiac cell of the same cell type and the promoter is active in a differentiated form of said cell.
- the promoter is a differentiated cardiac cell-specific promoter and the eukaryotic cell is a cardiac cell, preferably a primary cardiac cell.
- a particularly preferred promoter is the MHCK7 promoter if the eukaryotic cell is a cardiomyocyte.
- a further preferred promoter is the human eukaryotic elongation factor 1A1 (EEF1A1) gene promoter if the eukaryotic cell is a. cardiac fibroblast, a preadipocyte or an epicardial mesothelial cell.
- the promoter for the conditional immortalization of parenchymal cells is a cell type-specific promoter whose expression is relatively high and constant during phenotypic switching, i.e. is not much different between cells in the proliferation and differentiation stage.
- Our RNA-Seq analyses has yielded several cardiomyocyte-specific genes whose expression changes little during phenotypic switching, including the cardiac tropin T (TNNT2) gene.
- the promoter of this gene is used to generate conditionally
- immortalized cardiomyocytes Further provided is thus a. vector as described herein comprising an immortalizing gene under transcriptional control (in operative linkage) with the TNNT2 gene promoter.
- promoters that are active in differentiated forms of cells include the ectoderm-specific Nes promoter, endoderm-specific Afp promoter, mesoderm-specifie Mespl and T promoter, the epithelial Amyle, A.qp5, Cftr,
- Serpinala/7and Ttr promoter the hematopoietic cell-specific Was promoter, the macrophage/microglial cell/Kupffer cell/osteoclast/histiocyte-specific CD68 promoter, the antigen-presenting cell-specific Clec7a, Dc-stamp, Fscnl and Hla- Dra promoter, the pancreocyte-specific Amy2a 1/2/3/4/5, Ins 1/2 and Pdxl promoter, the adipocyte-speeifie Adipoq, Fabp4 and Lep promoter, the podocyte-specific Npshl/2 promoter, the keratinocyte-specific HPV LCR, EBV ED-L2 and
- Krtl/3/5/14 promoter the pituitary gland cell-specific Cga, Ghl/2 and Prl promoter, the pneumocyte-specific Sftpb /c promoter, the renal tubular cell-specific Ggtl and Sglt2 promoter, the neuron-specific Aldhlll, Camk2a, Dbh, Dlx5/6, Eno2, Gadl, Grial, Kcncl, Nfh, Pdgfb, Penk, pUNISHER, Slcl7a6/7/8, Stmn2, Synl, Tacl, Th and Tubala promoter, the neuron and astrocyte-specific Slcla2 promoter, the neuron- and tubular renal cell-specific Gls promoter, the glial cell-specific Gfap promoter, the ohgodendrocyte-specific Mag and Mbp promoter, the photoreceptor cell-specific Crx, Grkl, Nrl, Opnll/m/sw and Opn
- the promoter is preferably not a (r)tTA-dependent transactivation promoter.
- the promoter that is operably linked to said immortalization gene is preferably not a promoter that has tetO sequence for (r)tTA- dependent transactivation.
- the vector preferably does not encode a tetracycline-regulated transactivator.
- the term "immortalization gene” refers to a gene encoding a protein that triggers cell division, inhibits (programmed) cell death, and/or promotes telomere synthesis.
- a vector according to the invention comprises at least one immortalization gene. Hence, more than one, such as two,
- a vector according to the invention comprises one or more immortalization genes, more preferably one. Any immortalization gene known in the art can be used in the vector according to the invention. Examples of suitable immortalization genes include genes encoding the polyomavirus T antigens, the adenovirus E1A and E1B gene products, the papillomavirus E6 and E7 proteins, the hepadnavirus X protein, the B]pstein-Barr virus EBNAs, LMPs, BALF.1. protein, BARF1 protein, BCRF1 protein and BART gene products, the Kaposi's sarcoma virus-associated
- Bmil, Cbx7 and Cbx8), anti- apoptotic/autophagic/necroptotic/necrotic proteins e.g. apollon, cIAPl, cIAP2, ILP2, livin/MLIAP, NIAP, survivin, Al, Bcl-2, Bcl2-L-10, Bcl-B, Bcl-W, BC1-XL, Bfl-l, BOO/DIVA, Mcl-1, NR-13, vBcl-2, vIAP, C-FLIP, V-FLIP, adenovirus E3-6.7k protein, RIDa, RID6, E3-14.7k protein, African swine fever virus A179L [5-HL] protein, baculovirus p35, cytomegalovirus 62.7, pUL37xl [vMIA], UL36 [vICA], vIRA, Epstein-Barr virus BHRF1 protein, fowlpox
- telomerase reverse transcriptase as well as carcinogenic mutants of cellular oncogenes and tumor suppressor genes.
- the telomerase reverse transcriptase as well as carcinogenic mutants of cellular oncogenes and tumor suppressor genes.
- immortalization gene encodes SV40 LT or a variant thereof, preferably a temperature-sensitive variant, preferably temperature-sensitive mutant isA.58.
- inducible regulator refers to a regulator the activity of which can be induced by an external factor, such as a Ligand that can be added to or removed from a. composition to induce or repress the activity of the regulator.
- an external factor such as a Ligand that can be added to or removed from a. composition to induce or repress the activity of the regulator.
- Suitable regulators for use in the invention are described herein elsewhere. Further reference is made to Weber and Fussenegger 2006, which is incorporated by reference herein, for a description of inducible systems and regulators that can be used in accordance with the invention.
- operably linked refers to the association of nucleic acid sequences on the vector so that the function of one is affected by the other.
- An inducible regulator operably linked to the promoter sequence means that the activity of the promoter sequence is regulated by the inducible regulator.
- At least one immortalization gene operably linked to the promoter sequence means that the promoter initiates transcription of the at least one immortalization gene.
- the inducible regulator can either be a repressor or an activator, i.e. repress or activate the activity of the promoter.
- the inducible regulator is a repressor.
- the term "response element" refers to a nucleic acid or protein sequence, which, when bound by a ligand or ligand-inducible regulator, causes a decrease in transgene expression by affecting mRNA biosynthesis, RNA transport, mRNA stability, protein biosynthesis, protein stability, protein transport or protein activity.
- a response element refers to a sequence, which effects an increase or decrease in gene expression when bound by a nucleic acid-binding (e.g. DNA-binding) protein.
- the "response element” is preferably a nucleic acid sequence.
- inducible promoter systems are well known in the art. Examples of inducible promoter systems that can be used in a vector according to the invention include promoter systems regulated by antibiotics (e.g. tetracycline,
- cytokines e.g. interferons, interleukins, tumor necrosis factor
- steroid hormones e.g. dexamethasone, ecdysone, [4-hydroxy]tamoxifen
- acetaldehyde ethanol, forskolin, glucose, insulin, metals, mifepristone, nitric oxide, genotoxic, metabolic or oxidative stress, hypoxia, light or temperature.
- a preferred inducible promoter system is a Tet-inducible promoter system.
- the Tet expression system can be a Tet-On or a Tet-Off system. Briefly, in the Tet-On system, transcription is active in the presence of Tc or a Tc derivative like doxycycline (Dox). In the Tet-Off system, transcription is inactive in the presence of Tc or Dox.
- TetR Tet repressor DNA binding protein
- tTA Tc-controLled transactivater protein
- This fusion protein regulates expression of the target gene that is under transcriptional control of a Tc-response element (TRE), as part of the promoter sequence in a vector according to the present invention if a Tet-Off system is used.
- TRE Tc-response element
- TRE typically consists of multiple repeats of a 19-nucleotide tetO sequence (TCCCTATCAGTGATAGAGA) separated by spacer sequences, and is recognized by TetR.
- TetR 19-nucleotide tetO sequence
- tTA binds to the TRE and activates transcription of the target gene.
- Tc or Dox In the presence of Tc or Dox, tTA can no longer bind to the TRE, and target gene expression is lost.
- rtTR reverse Tc-controlled repressor protein
- the Tet-On system is based on a reverse Tc-controlled transactivator designated rtTA.
- rtTA is a fusion protein comprised of the TetR and the VP16 transactivation domain. However, due to a four amino acid change in the TetR DNA binding moiety the binding characteristics of rtTA are altered. Contrary to tTA rtTA recognizes the tetO sequences in the TRE of the target transgene in the presence of Tc or Dox. Thus, in the Tet-On system, transcription of the TRE- regulated target gene is stimulated by rtTA only in the presence of Tc or Dox.
- TetR is fused to a KRAB domain yielding a Tc-controlled repressor protein (tTR). Binding of tTR to a TRE located in the vicinity of a promoter inhibits its activity. In the absence of Tc or Dox, tTR binds to the TRE and represses target gene expression. In the presence of Tc or Dox, tTR can no longer bind to the TRE, and target gene expression is induced.
- Tc-controlled repressor protein tTR
- the LacR system functions by regulating transcription of a target gene with a promoter that contains lac operator (lacO) sequences to which LacR can bind.
- Expression of the target gene is induced by isopropyl-B-D-thiogalactopyranoside (IPTG). After binding to IPTG, LacR undergoes a conformational change strongly weakening its interaction with lacO sequences thereby allowing transcriptional activation of the promoter.
- IPTG isopropyl-B-D-thiogalactopyranoside
- the inducible regulator is a Tc-responsive transcriptional repressor
- the response element is a TRE.
- a suitable inducible and reversible expression system for use in accordance with the invention is a ligand-inducible degron.
- a suitable, but non limiting, example is an auxin-inducible degron.
- Suitable ligand-inducible degrons that can be used in accordance with the invention are, for instance, described in Bonger et al. (20.1.1), Holland et al. (20.1.2) and Navarro et al. (2016), which are incorporated herein by reference. Expression of the
- immortalization factor fused to a degron can be regulated using any one the promoters described herein above.
- a particularly preferred vector is a vector as shown in Figure 2.
- the vector system used for the reversible immortalization in accordance with the present invention is based on an inducible (i.e. ligand-controlled) HIV type 1 (HIV1) vector system developed by Szulc and coworkers.
- HIV1 HIV type 1
- the starting construct pLVET; https://www.addgene.0rg/11644/
- TRSs transcriptional regulatory sequences
- Figure 2A the coding sequences of immortalization genes
- Tc or Dox in Figure 2A immortalization gene expression is blocked by autorepression ( Figure 2A).
- ligand e.g. Tc or Dox
- tTR undergoes a conformational change, which no longer allows it to bind to its target sequence and to inhibit immortahzation gene expression ( Figure 2B). Accordingly, in culture medium with ligand, cells undergo
- the ligand-dependent (e.g. Tc- or Dox-dependent) expression of the immortalization gene(s) typically changes the properties of (differentiated) cells causing them to adopt a more undifferentiated phenotype.
- the (immortalised) cells (largely) maintain their epigenetic memory allowing them to (spontaneously) redifferentiate following shutdown of immortalization gene expression (i.e. Tc or Dox removal).
- atrial cardiomyocytes showed well-developed sarcomeres (i.e. contractile elements), were excitable (i.e.
- pLVET-tTR- KRAB Molecular cloning procedures using the starting construct (pLVET-tTR- KRAB) described by Szulc el al. (2006) were not straightforward due to: (1) the lack of convenient restriction enzyme/recombinase recognition sequences at strategic positions in this construct and (2) the specific arrangement of certain genetic elements. Therefore, a genetically modified version of pLVET-tTR-KRAB was generated by: (1) removing the promoter driving transgene expression (i.e. the human EEF1A1 gene promoter), (2) insertion of a multiple cloning site downstream of the HIV1 CTS and (3) removing the coding sequence for the enhanced green fluorescent protein (eGFP). Through these genetic modifications, insertion into the plasmid of all kinds of transgenes (with different promoters driving the expression of the desired RNA/protein-coding sequences) has become very easy.
- the promoter driving transgene expression i.e. the human EEF1A1 gene promoter
- eGFP enhanced green
- the invention further provides a genetically modified eukaryotic cell provided with a vector according to the invention.
- said cell comprises at least one immortalization gene operably linked to a promoter sequence, preferably a cell type- or tissue-specific promoter and/or a promoter that is active in a differentiated form of said cell, which is under the control of an inducible regulator.
- a "genetically modified eukaryotic cell” refers to a eukaryotic cell which contains a nucleotide sequence and/or protein or is
- this nucleotide sequence is at least the at least one immortalization gene.
- the cell is transiently or stably transfected or transduced with one or more nucleic acid molecules.
- the cell according to the invention comprises the inducible promoter sequence, the regulator sequence operably linked with said promoter sequence and the at least one immortalization gene operably linked with said inducible promoter sequence in its genome. This can, for instance, be achieved if the cell is transduced with a viral vector according to the invention and the indicated nucleotide sequences have been introduced in the cell's chromosomal DNA.
- the eukaryotic cell is provided with a vector according to the invention using persisting episomes.
- persisting episomes Reference is made to Lufino et al. (2008), which is incorporated by reference herein, for suitable methods.
- the eukaryotic cell is provided with a vector according to the invention using non-cytopathogenic RNA virus replicons. Reference is made to Schott et al. (2016), which is incorporated by reference herein, for suitable methods. By using such approaches, the immortalization gene is not incorporated into the cell's genome.
- the genetically modified eukaryotic cell is preferably a primary cell or progeny thereof.
- a "primary cell” refers to a cell, that is cultured directly from a subject.
- a "progeny" of a primary cell refers to a cell of any subsequent generation that has been derived from a primary cell through cell division.
- the genetically modified eukaryotic cell is preferably a human cell, a rat cell, a mouse cell, a canine cell or a porcine cell.
- the cell can be a heart cell, a blood vessel cell, a cell of the gastrointestinal, respiratory or urogenital tract ⁇ e.g. a gut cell, a kidney cell, a liver cell, a lung cell, a pancreatic cell, a stomach cell and a prostate cell), a brain cell, a nerve cell, a skin cell, a glandular cell, a skeletal or smooth muscle cell, a bone cell, a cartilage cell, a connective tissue cell, a fat cell, a hematopoietic cell, a sensory organ cell or any other cell type of the body.
- the cell can be a differentiated cell of the specified type.
- the differentiated cell can be isolated from embryonic, fetal, neonatal, juvenile or adult tissue.
- a differentiated cell is provided with a vector of the invention and triggered to dedifferentiate at least in part, such that the cell proliferates or keeps proliferating. The dedifferentiation that allows the
- the genetically modified eukaryotic cell is preferably a cardiac cell. It is preferably an atrial cardiac cell, a cardiomyocyte, a cardiac fibroblast, an epicardial mesothelial cell, a cardiac nodal cell or a cardiac Purkinje cell.
- the cell is preferably a primary cardiac cell, preferably a human, rat, mouse, canine or porcine cardiac cell.
- a cell line comprising a plurality of cells according to the invention.
- a "cell line” as used herein refers to a propa gated culture of cells. Said cell line preferably comprises a phu'ality of primary cells or progeny thereof. As used herein a "plurality of cells" refers to at least 2 cells. However, a cell line preferably comprises multiple cells. Hence, a. plurality preferably refers to at least 3, 4, 5, 10, 100, 500, 1000 or more cells.
- the primary cell or progeny thereof is preferably a mammalian cell, such as a mouse, rat or human cell or an avian cell, more preferably a mammalian cell.
- the cell is a human cell.
- the cell can be any type of cell derived from a mammal or bird .
- Examples are a cardiac cell, cardiomyocyte, cardiac or other fibroblast, cardiac or other myofibroblast, cardiac valve or other interstitial cell, cardiac Purkinje cell, vascular cell, smooth muscle cell, pericyte, endothelial cell, epicardial mesothelial or interstitial cell, pericardial mesothelial or interstitial cell, pleural mesothelial or interstitial cell, peritoneal mesothelial or interstitial cell, basal cell, apical cell, brain cell, neuron, glial cell, astrocyte, satellite cell, oligodendrocyte, Schwann cell, microglial cell, ependymal cell, liver/hepatic cell, hepatocyte, hepatic stellate/Ito cell, Kupffer cell, ductal cell, blood/hematopoietic cell, bone marrow cell, blast cell, leukocyte, granulocyte, macrophage, monocyte, megakaryocyte, lymphocyte
- a cell according to the invention preferably a primary cell or progeny thereof, is a cardiac cell, such as a cardiac fibroblast, a cardiomyocyte or an epi cardial mesothelial cell. It is further preferred that the cell is a cardiac cell and the promoter is a differentiated cardiac cell- specific promoter.
- a "differentiated cardiac cell-specific promoter" refers to a promoter that is specific for a differentiated form of a cardiac cell.
- said cell or cell line according to the invention is a proliferative cell or cell line.
- the cell or cell line is for instance cultiu'ed in the presence of the ligand of the inducible regulator operably linked to the promoter, which ligand induces transcription of the immortalization gene in the cell or in the cells of the cell line.
- the cell or cell line is cultured in the absence of a ligand of the inducible regulator operably linked to the promoter, which ligand inhibits transcription of the immortalization gene in the cell or in the cells of the cell line.
- the cell or cell line according to the invention is a differentiated or redifferentiated cell or cell line.
- redifferentiated in this context refers to the differentiation of a cell or cells originally derived from a differentiated cell, e.g. a primary cell or a progeny cell thereof, which has been immortalized with a method of the invention.
- kits of parts comprising a cell or cell line according to the invention and an agent capable of activating or repressing said inducible promoter.
- the specific agent present in the kit of parts depends on the inducible system that is used in the vector provided to the cell or cell line.
- Inducible systems and the respective agents that activate or inhibit the inducible promoter thereby initiating or inhibiting transcription of the target nucleic acid sequence(s), i.e. the one or more immortalization genes in the present invention are known in the arts and examples have been described above.
- a Tc-mducible promoter system which can be a. Tet-On system or a Tet-Off system is used in the vector, cell and methods of the present invention.
- the cell has been provided with a vector wherein the inducible regulator is a.
- Tc-responsive transcriptional repressor or activator and the response element is a TRE, and the agent capable of activating or repressing the inducible promoter is a Tc class antibiotic.
- Tc class antibiotic refers to Tc or a compound that has the same effect of Tc in a Tet expression system, such as Dox.
- Preferred Tc class antibiotics are Tc and Dox.
- the kit of parts may further comprise one or more components facilitating proliferation, survival and differentiation of the cell or cell line according to the invention. The specific components may depend on the type of cell or cell line, e.g.
- said one or more components are selected from the group consisting of natural or synthetic extracellular matrix components (e.g. collagen, fibronectin, gelatin, laminin, proteoglycans, vitronectin and derivatives thereof), anti-oxidants and vitamins (e.g.
- angiotensin angiotensin, dexamethasone, endothelin, growth hormone, insulin, phenylephrine, prostaglandins and [para] thyroid hormone
- agonists and antagonists of the Akt, AMPK, apoptosis, ErbB/HER, estrogen, HGF/c-Met, Hippo/YAP, insulin, JAK/STAT, MAPK/ERK, mTOR, NF- ⁇ , Notch, ⁇ 3, SCF/c-Kit, TGF-6/BMP, TLR, VEGF and Wnt signaling pathways e.g.
- adipokine bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor, fibroblast growth factor, insulin-like growth factor, interferon, interleukin, myokine, nerve growth factor, neuregulin, platelet- derived growth factor, tumor necrosis factor, vascular endothelial growth factor, wnt, Dkk and sFRP family members, CHIR99021, dorsomorphin, famotidine, IWP3, IWR1, noggin, SB208, SB203580, SB431542 and XAV939), L-carnitine, (phospho)creatine, polyamines and (phosphoenol)pyruvate.
- the kit of parts comprises a human cardiac cell or cell, line and the kit further comprises one or more components selected from the group consisting of natural or synthetic extracellular matrix components (e.g. collagen, fibronectin, gelatin, laminin, proteoglycans, vitronectin and derivatives thereof), anti-oxidants and vitamins (e.g.
- histone deacetylase inhibitors butyric acid, [suberoylanilide] hydroxamic acid, trichostatin A and valproic acid
- DNA methyltransferase inhibitors e.g. 5- azacytidine, decitabine, hydralazine and zebularine
- caspase inhibitors e.g. 5- azacytidine, decitabine, hydralazine and zebularine
- Akt Akt
- AMPK apoptosis
- ErbB/HER estrogen
- HGF/c-Met Hippo/YAP
- insulin insulin
- VEGF vascular endothelial growth factor
- Wnt signaling pathways e.g. activin, adipokine, bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor, fibroblast growth factor, insuhn-hke growth factor, interferon, interleukin, myokine, platelet-derived growth factor, tumor necrosis factor, vascular endothelial growth factor, wnt, Dkk and sFRP family members, CHIR99021, dorsomorphin, famotidine, IWP3, IWR1, noggin, SB208, SB203580, SB431542 and XAV939), L- carnitine, creatine, polyamines, pyruvate and combinations thereof.
- activin e.g. activin, adipokine, bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor,
- Also provided is a method for generating one or more conditionally immortalized cells comprising introducing one or more vectors according to the invention into one or more eukaryotic cells resulting in. one or more genetically modified eukaryotic cells.
- "Provided with a vector” as used herein preferably refers to transfection or transduction of the one or more primary cells with one or more vectors.
- the vector according to the invention is a viral vector, more preferably a lentiviral or other retroviral vector, and the one or more primary cells are transduced with said vector.
- Preferred vectors used in the methods of the invention are preferred vectors described herein above.
- the promoter is a cell type- or tissue-specific promoter and/or a promoter that is active in a differentiated form of said cell, more preferably a cell type-specific promoter. It is further preferred that at least one immortalization gene encodes SV40 LT or a variant thereof, preferably a temperature-sensitive variant, preferably temperature-sensitive mutant isA58.
- the eukaryotic cell that is provided with the vector is preferably a primary cell or progeny thereof, preferably from a mammal or a bird. It is further preferred that the cell, preferably a primary cell or progeny thereof, is a cardiac cell, such as a cardiomyocyte, cardiac fibroblast or pericardial mesothelial cell. In a particularly, preferred embodiment, the cell is a cardiac cell and said promoter is a differentiated cardiac cell-specific promoter, more preferably the chimeric striated muscle-specific MHCK7 promoter.
- conditionally immortalized cell or cells immortalization and/or proliferation of the cell or cells can be obtained by inducing expression of the one or more immortalization genes.
- a method of the invention further comprising culturing the one or more conditionally immortalized cells under conditions whereby transcription of the one or more immortalization genes is induced.
- the method further comprises culturing the primary cells provided with said one or more vectors in the absence of an agent that inhibits activity of the promoter.
- a method of the invention further comprises culturing primary cells provided with said one or more vectors in the absence of a Tc class antibiotic thereby activating said promoter and allowing transcription of said at least one immortalization gene.
- the method further comprises culturing the primary cells provided with said one or more vectors in the presence of an agent that induces activity of the promoter resulting in transcription of the at least one immortalization gene.
- an agent that induces activity of the promoter resulting in transcription of the at least one immortalization gene For instance, when using a Tet-On system, a method of the invention further comprises culturing primary cells provided with said one or more vectors in the presence of a Tc class antibiotic which induces release of the inducible repressor from said response element thereby activating said promoter and allowing transcription of said at least one immortalization gene.
- the methods of the invention may further comprise stimulating differentiation of the conditionally immortalized cell or cells.
- a method according to the invention may further comprise culturing the one or more conditionally immortalized cells under conditions whereby transcription of the one or more immortalization genes is inhibited.
- the method further comprises culturing the primary cells provided with said one or more vectors in the presence of an agent that inhibits activity of the promoter.
- a method when using a Tet-Off system., a method, of the invention further comprises culturing primary cells provided with said one or more vectors in the presence of a Tc class antibiotic thereby inhibiting the activity of said promoter and the transcription of said, at least one immortalization gene.
- the method further comprises culturing the primary cells provided with said one or more vectors in the absence of an agent that induces activity of the promoter.
- a. method of the invention further comprises culturing primary cells provided with said one or more vectors in the absence of a Tc class antibiotic thereby inhibiting the activity of said promoter and the transcription of said at least one immortalization gene.
- Inducing differentiation, proliferation and/or survival by inhibition of transcription of the immortalization gene may be accelerated or improved by the addition of one or more components that facilitate such differentiation,
- a method according to the invention further comprises culturing the one or more conditionally
- immortalized cells under conditions whereby transcription of the one or more immortalization genes is inhibited and in the presence of one or more components facilitating sm*vival and/or differentiation of said cells. Stimulation of proliferation is not desired following shut down of immortalization gene expression. In the proliferative state it may be attractive to add components that promote cell proliferation and survival while during cell differentiation it may be useful to add components that enhance cell differentiation and survival.
- Said one or more components are preferably selected from the group consisting of natural or synthetic extracellular matrix components (e.g. collagen, fibronectin, gelatin, laminin, proteoglycans, vitronectin and derivatives thereof), anti-oxidants and vitamins (e.g. ascorbic acid [2-phosphate]/vitamin C, ⁇ - tocopherol/vitamin E, glutathione, N-acetylcysteine, Qter, quercetin, resveratrol, retinoic acid/vitamin A, vitamin ⁇ - ⁇ , I3 ⁇ 4 and B12, catalase, superoxide dismutase and glutathione peroxidase), trace elements (e.g.
- natural or synthetic extracellular matrix components e.g. collagen, fibronectin, gelatin, laminin, proteoglycans, vitronectin and derivatives thereof
- anti-oxidants and vitamins e.g. ascorbic acid [2-phosphate]/vitamin C, ⁇ - to
- lipids e.g. cholesterol, phospholipids, sphingolipids and [un] saturated fatty acids
- reducing agents e.g. 2-mercaptoethanol, dithiothreitol, dithioerytJiritol and trie- [2- carboxyethyl]-phosphine hydrochloride
- histone deacetylase inhibitors butyric acid, [suberoylanilide] hydroxamic acid, trichostatin A and valproic acid
- DNA methyltransferase inhibitors e.g.
- adipokine bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor, fibroblast growth factor, insulin-like growth factor, interferon, interleukin, myokine, nerve growth factor, neuregulin, platelet- derived growth factor, tumor necrosis factor, vascular endothelial growth factor, wnt, Dkk and sFRP family members, CHIR99021, dorsomorphin, famotidine, IWP3, IWR1, noggin, SB208, SB203580, SB43.1.542 and XAV939), L-carnitine, (phospho)creatine, polyamines and (phosphoenol)pyruvate. Therefore, in a.
- the kit of parts comprises a human cardiac cell or cell line and.
- the kit further comprises one or more components selected from the group consisting of natural or synthetic extracellular matrix components (e.g. collagen, fibronectin, gelatin, laminin, proteoglycans, vitronectin and derivatives thereof), anti-oxidants and vitamins (e.g.
- Akt Akt
- AMPK apoptosis
- ErbB/HER estrogen
- HGF/c-Met Hippo/YAP
- insulin insulin
- VEGF vascular endothelial growth factor
- Wnt signaling pathways e.g. activin, adipokine, bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor, fibroblast growth factor, insulin-like growth factor, interferon, interleukin, myokine, platelet-derived growth factor, tumor necrosis factor, vascular endothelial growth factor, wnt, Dkk and sETRP family members, CHIR99021, dorsomorphin, famotidine, IWP3, IWRl, noggin, SB208, SB203580, SB431542 and XAV939), L- carnitine, creatine, polyamines, pyruvate or combinations thereof.
- activin e.g. activin, adipokine, bone morphogenetic protein, chemokine, colony-stimulating factor, cytokine, epidermal growth factor, fibroblast growth factor
- Conditionally immortalized cells using the invention have a. wide variety of application. They are, for instance, of great interest as model systems for, optionally high -throughput, screening of chemical libraries and evaluation of experimental drugs. Also, experiments with cells reversibly immortalized using the invention may provide an excellent alternative to the use of animals in
- Cells and cell lines according to the invention or prepared in accordance with the invention are further suitable as disease model and/or for target identification, e.g. in disease models, for fundamental research, cell therapy and/or tissue engineering.
- FIG. 1 Example of a vector system used for the reversible cell immortalization in accordance with the invention.
- A In the absence of Tc/Dox, immortalization gene expression is repressed facilitating cell differentiation.
- B In the presence of Tc/Dox, immortalization gene expression is induced stimulating cell proliferation.
- LTR HIV1 long terminal repeat.
- W HIV1 packaging signal.
- RRE HIV1 Rev-responsive element.
- cPPT HIV1 central polypurine tract and
- TRS transcriptional regulator sequence (i.e.. promoter)
- IRES encephalomyocarditis virus internal ribosome entry site.
- tTR coding sequence of the hybrid Tc-controlled transcriptional repressor TetR-KRAB (Deuschle et al., 1995).
- TRE Tc-responsive promoter element consisting of 7 repeats of a 19- nucleotide tetO sequence.
- FIG. 3 Conditional immortalization of rat neonatal atrial cardiomyocytes (naCMCs).
- A Scheme of the procedure used for the reversible immortalization, amplification and subsequent redifferentiation of naCMCs.
- A atrium. Ori, bacterial origin of replication.
- Amp H Escherichia coli B-lactamase gene.
- MHCK7 chimeric striated muscle-specific promoter (Salva el al., 2007).
- LT coding sequence of the temperature-sensitive mutant LT protein isA58 (Loeber et al., 1989).
- WHVPRE woodchuck hepatitis virus posttranscriptional regulatory element. For an explanation of the other abbreviations, see the legend of Figure 2.
- (B) Bright-field images of a single cell (day 6) in an naCMC culture showing Dox- dependent clonal expansion (days 7, 9 and 10).
- C-E Analysis by western blotting (C, D) and immunocytology (E) of SV40 LT protein expression in conditionally immortalized naCMC (iaCMC) cultures before (day 0) and 3, 6, 9 and 12 days after Dox removal.
- FIG. 4 Morphology, proliferative activity and apoptosis analysis of iaCMCs.
- A Bright-field images of proliferating iaCMCs (iaCMC-dO), iaCMCs at differentiation day 9 (iaCMC-d9), naCMCs at culture day 1 (naCMC-dl), and naCM Cs at culture day 9 (naCMC-d9).
- D Quantification of cell numbers in iaCMC cultures with or without Dox.
- E Fluoromicrograph of an na.CMC-d3 culture that was not subjected to mitomycin C treatment following double immunostaining for Ki-67 and sarcomeric u-aetinin.
- the Ki-67 1 7a-aetinin- cells observed in this culture mainly result from, uninhibited proliferation of cardiac fibroblasts (data not shown).
- F Fluorescence images of proliferating iaCMCs and of iaCMCs at different days after Dox removal labeled with Alexa Fluor-568-conjugated annexin V to assess externalization of phosphatidylserine as indicator of apoptosis.
- G Fluorescence images of a 9-day-old, mitomycin C-treated naCMC (naCMC-d9) culture labeled with Alexa Fluor-568-conjugated annexin V.
- FIG. 5 Cardiomyogenic differentiation potential of iaCMCs.
- A, C Analysis by reverse transcription- quantitative polymerase chain reaction (RT- qPCR) of the expression of the cardiac transcription factor genes Nltx2.5, Gata4 and Mef2c, the cardiac sarcomeric protein genes Actn2 and Myh6 (A), the "atrial” genes Nppa and Myl7 and the "ventricular” gene Myh7 (C) in naCMCs and rat neonatal ventricular cardiomyocytes (nvCMCs) at day 9 of culture and in iaCMCs on the indicated days of differentiation.
- mRNA. levels are expressed relative to those in 9-day-old naCMC (naCMC-d9) cultures, which were set at 1.
- naCMCs display low Myh7 gene expression.
- B, D Fluorescence images of proliferating iaCMCs and of iaCMCs at different days after Dox removal immunostained for sarcomeric a-actinin (red, B) or the atrial regulatory myosin light chain MLC2a (green, D).
- naCMCs and nvCMCs at culture day 9 served as positive and negative control for the MLC2a immunostaining, respectively. Cell nuclei have been visualized by staining with Hoechst 33342 (blue).
- FIG. 7 Electrophysiological properties of iaCMCs.
- A-E Single-cell patch-clamp analysis of iaCMCs and naCMCs. Typical total membrane current traces (a) and action potentials (APs; b) of naCMCs (A), excitable iaCMCs (B) and inexcitable iaCMCs (C). The small inward current observed in (C) corresponds to the input stimulus.
- G, H Typical activation maps (G; isochrones are separated by 6 ms) and optical signal traces (H) of iaCMC cultures at different days after Dox removal showing an increase in conduction velocity (CV) and a decrease in AP duration (APD) with advancing iaCMC differentiation.
- CV conduction velocity
- APD AP duration
- Figure 8 Characterization by optical voltage mapping and 1-Hz electrical point stimulation of confluent monolayers of iaCMC clones #1 (A-C) and #6 (D-F).
- Typical activation maps (A, D; isochrones are separated by 6 ms) and optical signal traces (B, E) acquired a different days after Dox removal showing an increase in CV and a decrease in APD with advancing iaCMC differentiation.
- C, F Quantification of CV, APDao and APDso at 3, 6 and 9 days of iaCMC
- FIG. 9 Comparison by optical voltage mapping and 1-Hz electrical point stimulation of the electrophysiological properties of confluent monolayers of iaCMCs at day 9 of differentiation (iaCMC-d9) with those of HL-1 cells.
- Typical activation maps (A; 6-ms isoehrone spacing) and optical signal traces (C) showing a much slower CV (B) and APD (C) for the HL-1 cells as compared to the iaCMC-d9.
- Figure 10 Suitability of iaCMCs as in vitro atrial fibrillation (AF) model assessed by optical voltage mapping.
- A, F Typical optical signal traces of mock- (A) and tertiapin (F)-treated iaCMCs at day 9 of differentiation (iaCMC-d9) after high-frequency (10-50 Hz) electrical point stimulation.
- B Activation maps (6-ms isochrone spacing) of ia.CMC-d9 cultures showing 1 (left) or 2 (right) reentrant circuits.
- C-E Inducibility of reentry (C), arrhythmia complexity (D) and quantification of rotor frequency (E), in iaCMC cultures at 3, 6, 9 and 12 days of differentiation.
- FIG. 11 Suitability of ia CMCs as in vitiv model to assess the ⁇ - b locking potential of drugs by optical voltage mapping.
- A Immunofluorescence analysis of Ky 11.1 protein expression in iaCMC-d6 cultures and in 9-day-old naCMC cultures.
- FIG. 12 Comparison by optical voltage mapping and 1-Hz electrical point stimulation of the electrophysiological properties of confluent 9-day-old cultures of naCMCs, Dox-deprived eGFP-labeled iaCMCs (eGFP-iaCMCs) and 50% naCMCs-50% eGFP-iaCMCs.
- eGFP-iaCMCs Dox-deprived eGFP-labeled iaCMCs
- naCMCs-50% eGFP-iaCMCs 50% Bright-field images (upper panel) and
- Figure 13 Structural integration of iaCMCs into neonatal rat atrium.
- Figure 15 Activity of MHCK7 promoter in proliferating iaCMCs and in iaCMCs at different days after initiation of cardiomyogenic differentiation.
- A Map of lentiviral vector shuttle plasmid pLV.MHCK7.eGPT eGFP, eGFP-coding sequence.
- WHVoPRE optimized version of the WHVPRE (Schambach et al, 2006), SIN-LTR, 3' long terminal repeat containing a 400-bp deletion in unique region 3 rendering the corresponding lentiviral vector self-inactivating (Zufferey et al, 1998).
- WHVoPRE optimized version of the WHVPRE (Schambach et al, 2006), SIN-LTR, 3' long terminal repeat containing a 400-bp deletion in unique region 3 rendering the corresponding lentiviral vector self-inactivating (Zufferey et al, 1998).
- FIG. 18 Experimental setup of the transcriptome analysis of conditionally immortalized neonatal rat atrial myocytes (iAM-1 cells) undergoing one cycle of cardiomyogenic differentiation and dedifferentiation.
- Proliferating iAM-1 cells day 0
- total RNA from 4 independent samples was extracted for whole transcriptome shotgun sequencing (RNA-Seq: ⁇ 2x10 7 150-bp paired-end reads/sample).
- FIG. 19 Relative contribution of the 7 most abundant transcripts to the entire transcriptome of iAM-1 cells at different stages of cardiomyogenic differentiation and dedifferentiation. Cardiomyogenic differentiation causes increases in the expression of the sarcomeric protein-encoding genes Actcl, Tpml, Myh6 and Tnnt2, of the gene for sarcoplasmic/endoplasmic reticulum Ca 2+ transporting ATPaae 2 (Atp2a2) and of the gene encoding atrial natriuretic peptide (Nppa). Subsequent induction of proliferation leads to a drop in the expression of these genes.
- Figure 20 Evaluation of the similarity between the RNA. samples used for the RNA-Seq study of iAM-1 cells undergoing one cycle of cardiomyogenic differentiation and dedifferentiation by principal component analysis. PCI and PC2 represents 60% and 20% of the observed variation in transcript counts, respectively. Different RNA samples from the same stage have very similar transcriptomes and iAM-1 cells that underwent one cycle of differentiation and dedifferentiation (samples 9a-9d) strongly resemble the starting material (samples la- Id).
- Figure 21 Clonal expansion during a period of ⁇ 2 weeks of right atrial cells from a 21-week -old human fetus following transduction with LV.iMHCK7.LT- WT and maintenance in the presence of 100 ng/ml doxycycline (Dox).
- FIG. 22 Phase contrast images of conditionally immortalized human fetal atrial cardiomyocyte clone 7L#6 during proliferation (left image, + Dox) and following cardiomyogenic differentiation (i.e. at 9 days after Dox removal; right image, -Dox).
- the starting material was derived from the left atrium of an 18- week-old human fetus.
- FIG. 23 Fluoromicrographs of conditionally immortalized human fetal atrial cardiomyocyte clone 7L#4 during proliferation (upper panel, + Dox) and following cardiomyogenic differentiation (i.e. at 9 days after Dox removal; lower panel, -Dox).
- the starting material was derived from the left atrium of an 18-week - old human fetus.
- the cells were stained with the DNA-binding dye Hoechst 33324 (left column), with antibodies directed against the proliferation marker Ki-67 (middle column) or with antibodies recognizing the large T (LT) oncoprotein of simian virus 40.
- FIG. 24 Fluoromicrographs of a primary human fetal left atrial cardiomyocyte (pAM; left image) and of clone 7L#4 during proliferation (middle image, + Dox) and following cardiomyogenic differentiation (i.e. at 9 days after Dox removal; right image - Dox).
- the starting material was derived from the left atrium of an 18-week-old human fetus.
- the cells were stained with the DNA-binding dye Hoechst 33324 (blue) and with antibodies directed against the sarcomeric protein cardiac troponin T.
- conditionally immortalized human fetal atrial cardiomyocyte clones 7L#12 and 7L#4 following cardiomyogenic differentiation (i.e. at 12 days after Dox removal).
- the starting material was derived from the left atrium of an 18-week-old human fetus.
- A, B Typical optical voltage trace (A) and activation m ap (B) of clone 7L#12 monolayers following 1-Hz electrical point stimulation. The spacing between isochrones is 12 ms.
- Figure 26 Current clamp record of a spontaneously active clone 7I_#4 cell cultured for 16 days in Dox-free medium.
- FIG. 27 (A) Overview of the method to generate conditionally immortalized epicardial mesothelial cells (iEPDCs). (B) Microscopic images of mock- (left) and LV.ihEEFlal.LT-teA58 (right)-transduced EPDC cultures initially containing equal numbers of cells. (C, D) Immunocytological (C) and western blot (D) analysis of LT expression in cultures of iEPDCs kept in the presence of Dox (+ dox) or for the indicated days in its absence (- dox).
- LV.iMHCK7.LT-isA58 except for the presence of the human EEF1A1 promoter instead of the MHCK7 promoter to drive LT-fsA58 expression.
- hEEFlal human EEF1A1 promoter.
- tTS coding sequence of the hybrid tetracycline-controlled transcriptional repressor TetR-KRAB (previously abbreviated tTR).
- tTR coding sequence of the hybrid tetracycline-controlled transcriptional repressor TetR-KRAB
- FIG. 28 Phase contrast microscopy of iEPDC cultures treated according to the added scheme showing evidence of epithehal-mesenchymal and mesenchymal-epithelial transition.
- FIG 29 Conditional immortalization of brown preadipocytes (BPAs).
- BPAs brown preadipocytes
- A Scheme of the procedure used for the reversible immortalization, amplification and subsequent redifferentiation of BPAs. For an explanation of the abbreviations see the legend of Figures 2, 3, and 27.
- B Growth curves of primary BPAs (nBPAs) and of LT- transduced/expressing BPAs (tBPAs). While nBPAs stopped
- Figure 30 Dox- dependent LT expression and proliferation ability of murine tEJPA clone 6 at 40 and 100 PDs.
- A-C Analysis by immunocytology (A) and western blotting (B, C) of LT protein expression in PB40 and PB100 clone 6 tBPAs maintained for 0, 2, 4, 6 and 8 days in Dox-free medium.
- D Proliferation rate of PB40 and PB100 clone 6 tBPAs cultured in the absence or presence of 100 ng/ml Dox.
- Figure 31 Bright field images of murine clone 6 and 7 tBPAs cultured for the indicated days in Dox-free adipogenic differentiation medium.
- Figure 32 Analysis by RT-qPCR of the expression of brown fat cell markers by murine clone 6 and 7 tEiPAs cultured for the indicated, days in Dox-free adipogenic differentiation medium.
- FIG. 33 Adipogenically differentiated murine clone 6 and 7 tBPAs show increased glycerol production and Ucpl transcript levels following treatment with the broad spectrum adrenoreceptor agonist noradrenaline (NA) or with the 63 adrenoreceptor agonist CL316243.
- NA broad spectrum adrenoreceptor agonist noradrenaline
- CL316243 63 adrenoreceptor agonist
- FIG. 34 Oxygen consumption of adipogenically differentiated murine clone 6 and 7 tBPAs to consecutive treatments with the 63 adrenoreceptor agonist CL316243 or vehicle, the ATP synthase inhibitor oligomycin, the mitochondrial oxidative phosphorylation uncoupler/protonophore carbonyl cyanide-4-
- FCCP trifluoromethoxyphenylhydrazone
- FIG 35 Bright-field images of human clone 2 and 3 tBPAs at 16 days after the exposiu'e to adipogenic differentiation medium without (regimen 1 and 2) or with, (regimen 3) Dox.
- Figure 36 Bright-field images of human clone 2 and 3 tBPAs cultured for the indicated days in Dox-free regimen 2 adipogenic differentiation medium.
- FIG 37 Analysis by RT-qPCR of the expression of brown fat cell markers UCP1, PRDM16 and PPARGCIA (also known as PGC- la) by human clone 2 and 3 tBPAs subjected to adipogenic differentiation regimens 1 (-dox before diff, green line), 2 (-dox from diff, blue line) or 3 (+dox, red line).
- FIG 38 Analysis by RT-qPCR of the expression of brown fat cell markers PPARG and FABP4 (also known as AP2) by human clone 2 and 3 tBPAs subjected to adipogenic differentiation regimens 1 (green line), 2 (blue line) or 3 (red line).
- Figure 39 Analysis by RT-qPCR of the expression of brown fat cell markers by human clone 2 and 3 tBPAs subjected to regime 2 adipogenic differentiation.
- Figure 40 Glycerol release by adrenergically stimulated human clone 2 tBPAs measured at day 15 of adipogenic differentiation (regimen 2 without or with dexamethasone [Dex]).
- B Glycerol release by adrenergically stimulated human clone 3 tBPAs measured at the indicated days of regimen 2 adipogenic differentiation in the presence of Dex.
- FIG. 41 Glycerol release by adrenergically stimulated tBPA clones derived from 3 different individuals at day 16 of adipogenic differentiation
- DNA constructions were carried out with enzymes from Fermentas (Thermo Fisher Scientific, Breda, the Netherlands) or from New England Biolabs (Bioke, Leiden, the Netherlands) and with ohgodeoxyribonucleotides from Eurofins MWG Operon (Ebersberg, Germany) using established procedures or following the instructions provided with specific reagents.
- thermosensitive version of the oncogenic SV40 LT antigen (mutant teA58 also known as isA438A-V; Loeber et al, 1989), plasmid
- pAT153.SV40ori(-) (Dinsart et al, 1984) was incubated with PvuII and the 4.3-kb digestion product was recircularized with bacteriophage T4 DNA ligase to generate pAT153.SV40ori(-).dPvuII.
- pAT153.SV40ori(-).dPvuII was subsequently cut with Hindlll and PvuII and the large digestion product of 4.3 kb was combined with the hybridization product of oligodeoxyribonucleotides 5'
- telomere sequence 3' and 5' CCGAATTCTTTATCTTTCAGGTTCAGGG 3' (the initiation codon and the complement of the termination codon are underlined) to amplify the LT-coding sequence.
- the resulting PCR fragment was inserted into plasmid pJET1.2/blunt using the Clone JET PGR cloning kit (Thermo Fisher Scientific) to generate pJetl.2.LT-teA58.
- pJetl.2.LT-feA58 was incubated with Mssl and EcoRI and the 2.5-kb digestion product was combined with the 11.0-kb MssIxEcoRI fragment of lentiviral vector shuttle plasmid pLV.iMHCK7 to generate pLV.iMHCK.7.LT-isA58.
- pLV.iMHCK7 is a derivative of pLVET-tTR-KRAB (Szulc et al, 2006; Addgene, Cambridge, MA; plasmid number: 116444) in which the human EEF1A1 gene promoter and the Aequorea victoria eGFP-coding sequence were replaced by the striated muscle-specific MHCK7 promoter (Salva et al, 2007) and a. small polylinker containing unique Spel, Mssl, Pstl and EcoRI restriction enzyme recognition sequences.
- Mammalian expression plasmid pU.CAG.eGFP in which eGFP expression is driven by the CAG promoter (Niwa et al, 1991), was generated by replacing the human TBX5-encoding SallxNotl fragment of pU.CAG.hTBX5 (van Tuyn el al, 2007) with the eGFP-encoding SallxNotl fragment of Clontech's pEGFP construct (Takara Bio Europe, Saint-Germain-en-Laye, France).
- Lentiviral vector shuttle plasmid pLV.MEICK7.eGFP ( Figure 15) is a derivative of construct pLV.MHCK7.eYFP.WHVPRE (Bingen et al, 2014), in which the coding sequence for the Aequorea victoria enhanced yellow fluorescent protein and
- WHVPRE are replaced by the eGFP open reading frame and a mutated shortened version of the WHVPRE designated WHVoPRE (Schambach et al, 2006). Lentiviral vector production
- the 293T cells were cultured in high- glucose Dulbecco's modified Eagle's medium (DMEM; Life Technologies Europe, Bleiswijk, the Netherlands; catalogue number: 41966) with 10% fetal bovine serum (FBS; Life Technologies Europe).
- DMEM high- glucose Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- the transfection mixture which consisted of 35 ⁇ g of plasmid DNA and 105 ⁇ g of polyethyleneimine (Polysciences Europe,
- polypropylene ultracentrifuge tube (Beckman Coulter Nederland, Woerden, the Netherlands) was underlayed with 5 ml of 20% (wt/vol) sucrose in phosphate- buffered saline (PBS) and centrifuged for 120 minutes at 4°C with slow
- LV.MHCK7.eGFP particles were generated using the same procedure except for the use of pLV.MHCK7.eGFP instead of LV.iMHCK7.LT-isA58 as lentiviral vector shuttle plasmid.
- naCMCs were isolated from neonatal Wistar rat hearts and cultured as detailed elsewhere (Feola et ah, 2016). Briefly, rats were anaesthetized with 4-5% isoflurane inhalation. After adequate anesthesia had been confirmed by the absence of pain reflexes, hearts were excised. Atria were separated from the hearts, minced and dissociated by 2 subsequent 30-minute treatments with collagena.se type I (Worthington Biochemical, Lakewood, NJ) and DNase I (Sigma-Aldrich). Cells were pelleted by centrifugation for 10 minutes at RT and 160x# and suspended in Ham's F10 medium (Life Technologies Europe; catalogue number: 11550) supplemented with 100 units/mL of penicillin and 100 ⁇ ! of
- LV.iMHCK7.LT-isA58-transduced cells and naCMCs were subsequently maintained, in a 1:1 mixture of low-glucose DMEM (Life Technologies Europe; catalogue number: 22320) and Ham's F10 medium (DMEM/FIO) supplemented with 5% heat-inactivated HS, 1x penicillin-streptomycin, 2% BSA and sodium ascorbate to a final concentration of 0.4 mM and in DMEM/F10 with 10% heat-inactivated FBS, 1x penicillin-streptomycin and 100 ng/ml Dox or no Dox as indicated, respectively. Culture medium was replaced daily (naCMCs) or every 2-3 days (iaCMCs).
- nvCMCs For the isolation and culture of nvCMCs the same method was used as for naCMCs except that ventricular instead of atrial tissue of newborn rats served as starting material. HL-1 cells were cultured in 25-cm 2 cell culture flasks (Corning Life
- naCMCs were transduced with LV.iMHCK7.LT-teA58.
- iaCMCs were cultured in the absence of Dox for 3, 6, 9 and 12 days and characterized by a combination of molecular biological, cell biological, immunological and electrophysiological techniques.
- LV.iMHCK7.LT-fsA58-transduced iaCMCs were eGFP- labeled using the lentiviral vector designated LV.MHCK7.eGFP and passaged multiple times in the presence of Dox before use as donor cells to avoid carry-over of functional LV.MHCK7.eGFP particles (Ramkisoensing et al, 2012).
- Bound antigens were detected using Alexa 488- conjugated donkey anti-rabbit IgG (H+L) (Thermo Fisher Scientific, catalogue number: A21206) and Alexa 568-coupled donkey anti-mouse IgG (H+L) (Thermo Fisher Scientific, catalogue number: A.10037). These secondary antibodies were diluted 1:400 in PBS. Hoechst 33342 (10 ⁇ g/ ⁇ l; Thermo Fisher Scientific) was used to counterstain nuclei. Stained cells were visualized using a digital color camera- equipped fluorescence microscope (Nikon Eclipse 80i; Nikon Instruments ECurope, Amstelveen, the Netherlands).
- iaCMCs were cultured at low density in medium with or without 100 ng/ml Dox. At different days after culture initiation, cells were collected in PBS, mixed at a ratio of 1:1 with 0.4% Trypan Blue (VWR International, Amsterdam, the Netherlands) in PBS and briefly incubated at RT after which viable cells were counted using a hemocytometer. To distinguish proliferating from non-proliferating cells, monolayer cultures of naCMCs were immunostained with Ki-67-specific antibodies.
- nvCMCs treated for 24 hour with 1 ⁇ of the chemotherapeutic agent doxorubicin (Sigma-Aldrich) served as positive control for the apoptosis assay.
- RT-qPCR was performed as previously reported (Yu el al., 20.16). Briefly, iaCMCs were seeded at a density of 8x10 5 cells/well in 24- well cell culture plates and cultured for 1 day in medium containing 100 ng/ml Dox. The next day, cells were either lysed in TRIzol Reagent (Thermo Fisher Scientific) and total RNA was isolated using the RNeasy Mini kit (QIAGEN Benelux, Venlo, the Netherlands) or kept for 3, 6, 9 or 12 days in culture medium without Dox prior to cell lysis and RNA extraction.
- TRIzol Reagent Thermo Fisher Scientific
- RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad Laboratories) and gene expression levels were determined by PGR using the Bioline SensiFAST SYBR No-ROX kit (GC biotech) and intron-spanning primer pairs (Table 1). PGR amplifications were performed in a CFX96 Touch Real- Time PGR Detection System (Bio-Rad Rad Laboratories). Per target gene 3 independent experiments were performed consisting of 3 samples per experiment. Quantitative analyses were based on the method using CFX Manager software (Bio-Rad Rad Laboratories). PGR amphfications of the rat 18S rRNA gene (Rnl8s) were included for normalization purposes.
- Patch-clamp recordings were conducted at 20-23°C in naCMCs of culture day 2 to 4 and in iaCMCs which had been maintained for 3, 6, 9 and 12 days in Dox-free culture medium.
- cells were transferred from culture medium to a bath solution containing (in mM): 126 NaCl, 11 glucose, 10 HEPES, 5.4 KC1, 1 MgCh and 1.8 CaCl 2 (adjusted to pH 7.40 with NaOH).
- Pipettes had typical electrical resistances of 2-3 ⁇ in bath solution when filled with a solution containing (in mM): 80 potassium DL-aspartate, 40 KC1, 8 NaCl, 5.5 glucose, 5 HEPES, 5 EGTA, 1 MgCb, 4 Mg-ATP and 0.1 Na 3 -GTP (adjusted to pH 7.20 with KOH).
- the G ⁇ seal was formed by applying 10-ms voltage steps from 0 to +5 mV at 10 Hz. After reaching GO. seal, the holding potential was set to -50 mV, and the patch membrane was ruptured by gentle suction.
- the voltage and current commands were delivered to the MultiClamp 700B amplifier via the Digidata 1440A A/D converter.
- the latter instrument was controlled by MultiClamp 700B commander and pCLAMP 10 software (Axon CNS, Molecular Devices).
- the current and voltage outputs of the amplifier were continuously sampled at intervals of 100 ps and recorded onto a personal computer after low- pass filtering at 4 kHz with a four-pole Bessel filter. For data analysis, the estimated liquid junction potential of 11 mV was corrected.
- Atrial tissue from neonatal rats was used as graft recipient of iaCMCs.
- Two- day-old Wistar rats were anaesthetized by 4-5% isoflurane inhalation and adequate anaesthesia was confirmed by the absence of reflexes.
- the chest was opened and the inferior vena cava was cut off with scissors, the right atrium was punctured with a. 19-gauge needle.
- the heart was perfused through this needle with pre-warmed and oxygenated PBS containing 10 IU/ml heparin to flush out the blood.
- Two and a half ⁇ l of growth factor-reduced Matrigel (BD Biosciences) was mixed with 2.5 ⁇ l cell suspension containing 5x10 4 iaCMCs and injected into the bilateral atrial free walls using a 25- ⁇ 1 syringe equipped with a 33-gauge needle (Hamilton Robotics, Reno, NV).
- the atrial tissue including the injected area was excised and cultured as described by Brandenburger et al. (2012) with the following
- the atrial tissue was placed with the endocardial surface down onto the semi-porous polytetrafluoroethylene membrane (0.4 ⁇ m pore size) of a
- PICM0RG50 cell culture insert (Millipore) in a 35-mm diameter Petri dish containing 1 ml sterilized Tyrode's solution (TS; 136 inM NaCl, 5.4 mM KC1, 10 mM MgH 2 PO 4 , 1 mM MgH 2 PO 4 , 10 mM glucose, 0.9 mM CaCla) of RT and gradually warmed to 37°C.
- TS Tyrode's solution
- the TS was replaced with 1 ml pre-warmed low- glucose DMEM supplemented with 1% heat-inactivated FBS, 1x penicillin- streptomycin, lx B-27 supplement minus antioxidants (Life Technologies Europe) and 5 ⁇ Z-Asp-2,6-dichlorobenzoyloxymethylketone (Santa Cruz Biotechnology) and. the tissue was kept at 37°C in. humidified 95% air-5% CO 2 (culture conditions) until histological examination. Culture medium was replaced every 2 days. Whole tissue staining and confocal microscopy
- Neonatal rat atrial tissue was quickly washed 3 times with PBS and fixed by incubation for 30 minutes at 4°C in buffered 4% formaldehyde (Added Pharma, Oss, the Netherlands) followed by 3 quick washes with PBS and a 5-minute wash with PBST (0.1% Triton X- 100 [Sigma-Aldrich] in PBS). Next, aspecific binding sites were blocked by incubation for 1 hour at RT with 10% NDS in PBST.
- iaCMCs For monitoring the transfection efficiency of iaCMCs with plasmid DNA we used the eGFP-encoding mammalian expression plasmid pU.CAG.eGFP.
- iaCMCs were seeded at a density of 4.8x.10 5 cells per well in a 24-well cell culture plate and maintained in iaCMC culture medium with Dox. The next day, the cells were transfected with Lipofectamine 3000 reagent (Thermo Fisher Scientific) according to the manufacturer's instructions.
- plasmid DNA-lipid complexes containing 500 ng of pU.CAG.eGFP DNA 1 ⁇ l of P3000 reagent and 1.5 ⁇ l of Lipofectamine 3000 reagent diluted in Opti-MEM I reduced serum, medium (Thermo Fisher Scientific) were added per well, to 500 ⁇ l of iaCMC culture medium without Dox.
- the cells were processed for flow cytometry using a BD Accuri flow cytometer (BD Biosciences), (immuno)fluorescence microscopy and optical voltage mapping.
- the transfection medium was replaced with regular iaCMC culture medium without Dox 2 days after the addition of the lipoplexes.
- naCMCs As starting material for the conditional immortalization of naCMCs, we used low-densi ty cardiomyocyte-enriched cultures of primary cells i solated from the atria of 2-day-old Wistar rats. These cultures were transduced with lentiviral vector particles containing a Dox-inducible LT expression unit based on the monopartite lentiviral Tet-on system developed by Szulc et al. (2006).
- LT expression in this lentiviral vector system was driven by the strong hybrid striated muscle-specific MHCK7 promoter (Salva et al., 2007; Figure 3A) to minimize the likelihood of inadvertently immortalizing the ⁇ 12% non-cardiomocytes present in the primary atrial cell cultures (data not shown; Bingen et al., 2013).
- clone #5 showed the shortest APD and highest CV in this preliminary screen and was therefore picked for further investigation.
- Western blot analysis and immunofluorescence microscopy showed expression of LT in this clone to be tightly and effectively controlled by Dox ( Figure 3C-E).
- iaCMCs To investigate the cardiomyogenic differentiation potential of iaCMCs, the expression of cardiac marker genes in proliferating and differentiating iaCMC cultures was assessed by RT-qPCR analysis and compared with that of naCMCs and of native nvCMCs at culture day 9.
- Myofibril assembly nearly reached completion at day 6 after Dox removal., with most of the a-aetinin displaying the Z-line staining pattern typical of cardiomyocytes.
- myofibrils underwent further maturation resulting in cells with highly organized sarcomeres.
- iaCMCs After Dox removal, mRNA levels of the atrial n3 ⁇ 4toiuretic peptide-encoding Nppa gene and the atrial myosin light x ;hain 2 (Mlc2a)-encoding Myl7 gene were strongly upregulated in iaCMCs ( Figure 5C). Moreover, neither in the absence nor in the presence of Dox, iaCMCs expressed detectable amounts of ft-niyosin heavy chainTenmchng Myft 7 transcripts indicating that iaCMCs reacquire properties of atrial rather than ventricular cardipmyocytes when cultured in Dox-free medium.
- RT-qPCRs targeting genes encoding cardiac ion channels showed an increase in the mRNA levels of ScnSa/NaA.Q, Cocraalc/Cavl.2, Kcnj3fKii3.1, Kcnj5fKicS' A and Kcnj 12/Kir6.2 during the early stages of iaCMC differentiation (iaCMC-d3 and iaCMC-d6), which, later in the differentiation process (iaCMC-d9 and iaCMC-d.1.2), dropped to approximately equal levels as in naCMCs at culture day 9 ( Figure 6A-6E, respectively).
- transcript levels at the late stages of iaCMC differentiation were higher than those in day 9 naCMCs ( Figure 6F and 6G, respectively).
- the iaCMCs did not express detectable amounts of Kcnj2fKi r 2.1 at any stage in the differentiation process in contrast to naCMCs that had been cultured for 9 days ( Figure 6H).
- the average cell membrane capacitance of iaCMCs that had been cultured at low density for 3, 6, 9 and 12 days in the absence of Dox was 83.0 ⁇ 17.3, 108.9 ⁇ 38.5, 219.2 ⁇ 60.6 and 166.8 ⁇ 98.9 pF, respectively, as compared to 33.8*8.3 pF for naCMCs in 2- to 4-day old low density cultures (Figure 7E).
- the larger membrane capacitance and therefore cell surface area of iaCMCs may relate to their more flattened shape and explain why depolarization of these cells was slower than that of naCMCs (compare Figure 7Ab with Figure 7Bb).
- Another possible contributor to the relatively low upstroke velocity of excitable iaCMCs might be the strong outward currents produced by these cells, counteracting the inward currents.
- Cx43 was mainly detected in the perinuclear region (i.e. at the site of biosynthesis) but at days 9 and 12 of differentiation, most Cx43 was found in punctate patterns at the interfaces between iaCMCs.
- differentiated iaCMCs were subjected to 1-Hz electrical point stimulation, which caused the cells to contract at the pacing frequency. This result was corroborated by optical voltage mapping, which showed uniform radial spreading of excitatory waves from the site of electrical point stimulation in iaCMC cultures at day 9 of differentiation. Additional optical voltage mapping experiments revealed a gradual increase in CV ( Figure 7G and 71) and decrease in APD ( Figure 7H, 7J and 7K) with ongoing iaCMC differentiation.
- Optical voltage mapping of other clones of excitable iaCMCs yielded very similar results although not all of them reached the same maximum CV and minimum.
- APD as clone #5 (e.g. clone #1 and #6; Figure 8A-8C and 8D-8F, respectively).
- HL-1 cell line which was derived from the AT-l mouse atrial cardiomyocyte tumour lineage (Claycomb et al., 1998).
- confluent monolayers of iaCMCs at day 9 of differentiation and optimally maintained confluent cultures of HL-1 cells were subjected to optical voltage mapping following 1-Hz pacing.
- the CV in the HL-1 cultures was ⁇ 20-fold lower than in the iaCMC cultures ( Figure 9A and 9B) and HL-1 cells displayed greatly prolonged APs as compared to differentiated iaCMCs ( Figure 9C) characterized by a very slow upstroke.
- Kcnh2 Drug-induced ventricular arrhythmias due to inadvertent blocka.de of the Kvll.l channel, which is encoded by the Kcnh2 gene, represents a major safety concern in drug development (Kannankeril et al., 2010).
- Double immunostaining of these cells for Kvll.l and sarcomeric a-actinin showed that both cell types expressed the Kvll.1 protein and that it was concentrated around the nucleus and at the sarcolemma ( Figure 11A).
- iaCMCs could be used to identify unintended Kv11.1 blockers, the effect of exposing iaCMCs at day 6 of differentiation to 100 nM of the antihistamine astemizole, which was previously shown to efficiently block the Kv11.1 channel but no other cardiac ion channels (Delpon et al., 1999), was studied by optical voltage mapping.
- iaCMCs were labeled with eGFP by lentiviral
- iaCMCs would benefit greatly from them being well transfectable with plasmid DNA, especially since most viral gene transfer vectors (e.g. lentiviral and adeno-associated virus vectors) can accommodate only a limited amount of foreign genetic information.
- iaCMCs would be amenable to plasmid DNA transfection with Lipofectamine 3000. Near-confluent cultures of proliferating iaCMCs were lipofected with the eGFP-encoding mammalian expression plasmid pU.CAG.eGFP in Dox-free medium and transgene expression was assessed by direct fluorescence microscopy and flow cytometry at 2 and 9 days after Dox removal ( Figure 14A and 14B).
- transfected cells differentiated equally well into functional cardiomyocytes as their non- transduced counterparts judged from the results of a-actinin immunostaining ( Figure 14C) and optical voltage mapping ( Figure 14D) of the iaCM C cultures at 9 day after transfection.
- naCMCs transducing naCMCs with a lentiviral vector directing myocyte-selective and Dox- dependent expression of the SV40 LT antigen. Culturing of the resulting cells in medium with Dox caused their rapid expansion, while in Dox-free culture medium, the amplified cells spontaneously and synchronously differentiated into fully functional (i.e. excitable and contractile) naCMCs that were successfully used to develop a monolayer model of AF and for studying the APD-proIonging effects of drugs (asteinizole) and toxins (tertiapin).
- iaCMCs with a unique and easy-to-remember identifier
- the murine atrial myocyte line HL-1 has the most differentiated phenotype and is therefore most widely used.
- Side-by-side comparison of the electrophysiological properties of confluent monolayers of differentiated iaCMCs and HL-1 cells by optical voltage mapping showed an average CV for the HL-1 cultures of 1 cm/s, which is about 20-fold lower than that of iaCMC cultures and in line with previous reports (Dias et al., 2014). Since Ma et al reported a.
- confluent HL-1 cell monolayers are a blend of proliferating cells without cardiomyocyte functionality, which are electrically coupled to cells that phenotypically resemble embryonic atrial myocytes (Claycomb et al, 1998). Conversely, in the iaCMC cultures at 9 day of
- iaCMCs therefore provide a virtually unlimited supply of cardiomyocytes for diverse applications including: (1) development of acquired disea * se models, (2) identification of new therapeutic targets, (3) screening of drugs and toxins, (4) testing of new treatment modalities (e.g. gene and cell therapy), (5) production of biopharmaceuticals in bioreactors or encapsulated cell/tissue grafts, (6) improvement of tissue engineering approaches and (7) and ) fundamental research.
- the recent rapid progress in genome editing technologies will further expand the applicability of iaCMCs allowing them to be used as models for studying key a * spects of inherited cardiomyopathies.
- a highly attractive feature of the iaCMCs is that they spontaneously undergo cardiomyogenic differentiation in a synchronous and near quantitative manner in standard culture medium without Dox. Contrarily, generation of cardiomyocytes from embryonic or induced PSCs requires their properly timed treatment with various cocktails of growth factors and small molecules (Spater et al., 2014). This typically yields phenotypically heterogeneous populations of mostly immature cardiomyocytes contaminated with variable percentages of non- cardiomyocytes. Consequently, to obtain relatively pure populations of PSC-derived cardiomyocytes various different enrichment procedures have been developed.
- iAMs offer the possibility to study the molecular mechanisms involved in the transition of a differentiated cardiomyocyte that is no longer able to undergo cytokinesis into an actively dividing cell. This is particularly relevant given the growing interest in regeneration of mammalian hearts from within by stimulating cardiomyocytes surrounding the site(s) of cardiac injury to multiply themselves through cell division. Current findings regarding the molecular changes
- cardiomyocyte proliferation should be interpreted with caution due to the presence of other cell types (e.g. cardiac fibroblasts and inflammatory cells) in most test materials.
- iAMs do not suffer from this drawback making them a. potentially highly useful model, system, to study the mechanisms underlying cell cycle reentry and progression of cardiomyocytes.
- iaCMCs Following their differentiation in the absence of Dox, iaCMCs acquire properties of atrial rather than ventricular myocytes as evinced by the high-level expression in differentiated iaCMCs of "atrial" genes including Nppa, Myl7, Kcnj3 and. KcnjS and the lack, of expression of the "ventricular" Myh7 gene. Moreover, following 1-Hz pacing, differentiated iaCMCs display rapid contractions that strongly resemble those of naCMCs but are quite different from the slower contractions of nvCMCs (data not shown).
- RT-qPCR analysis of iaCMCs in different stages of differentiation shows a rapid increase in mRNA levels of cardiac transcription factors, ion channels, Ca ⁇ handling proteins and sarcomeric proteins shortly after Dox removal.
- these mRNA levels either stay fairly constant (as for the genes encoding cardiac transcription factors, sarcomeric and Ca 2+ handling proteins) or decline again to the approximate mRNA levels of naCMCs (Scn5a, Cacna1c, Kcnj3, Kcnj11) and/or proliferating iaCMCs (ScnSa, Cacna1c, Kcnd3, Kcnh2, Kcnj3).
- iaCMCs may provide an easy and cost- effective alternative for PSC-derived cardiomyocytes, especially when the conditional immortalization strategy can be expanded to other types of
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17152653 | 2017-01-23 | ||
EP17195811 | 2017-10-10 | ||
PCT/NL2018/050046 WO2018135948A1 (en) | 2017-01-23 | 2018-01-23 | Conditionally immortalized cells and methods for their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3571292A1 true EP3571292A1 (en) | 2019-11-27 |
Family
ID=61386877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18707762.3A Withdrawn EP3571292A1 (en) | 2017-01-23 | 2018-01-23 | Conditionally immortalized cells and methods for their preparation |
Country Status (4)
Country | Link |
---|---|
US (1) | US20200032213A1 (en) |
EP (1) | EP3571292A1 (en) |
CA (1) | CA3051162A1 (en) |
WO (1) | WO2018135948A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111297474B (en) * | 2019-12-19 | 2022-11-08 | 成都迈格因科技有限公司 | Individualized positioning and mapping system for auricular fibrillation focus |
CN114990071A (en) * | 2022-08-03 | 2022-09-02 | 广东乾晖生物科技有限公司 | Construction method of reversible immortalized liver cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2141241A1 (en) * | 2008-07-03 | 2010-01-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Senescence cells and methods for its production |
-
2018
- 2018-01-23 EP EP18707762.3A patent/EP3571292A1/en not_active Withdrawn
- 2018-01-23 WO PCT/NL2018/050046 patent/WO2018135948A1/en unknown
- 2018-01-23 US US16/480,280 patent/US20200032213A1/en not_active Abandoned
- 2018-01-23 CA CA3051162A patent/CA3051162A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200032213A1 (en) | 2020-01-30 |
WO2018135948A8 (en) | 2019-09-06 |
WO2018135948A1 (en) | 2018-07-26 |
CA3051162A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Victor et al. | Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts | |
Shinnawi et al. | Monitoring human-induced pluripotent stem cell-derived cardiomyocytes with genetically encoded calcium and voltage fluorescent reporters | |
US20230038168A1 (en) | Lineage Reprogramming to Induced Cardiac Progenitor Cells (iCPC) By Defined Factors | |
CN108431211A (en) | It is generated by multispectral system's hemopoietic forebody cell of genetic programming | |
Abou-Saleh et al. | The march of pluripotent stem cells in cardiovascular regenerative medicine | |
US20170306351A1 (en) | Engineering a heterogeneous tissue from pluripotent stem cells | |
Mikell et al. | HCMV miR-US22 down-regulation of EGR-1 regulates CD34+ hematopoietic progenitor cell proliferation and viral reactivation | |
JP5751548B2 (en) | Canine iPS cells and production method thereof | |
JP7072279B2 (en) | Method for producing pancreatic endocrine cells | |
US20200032213A1 (en) | Conditionally immortalized cells and methods for their preparation | |
Tolmachov et al. | Overexpression of connexin 43 using a retroviral vector improves electrical coupling of skeletal myoblasts with cardiac myocytes in vitro | |
Xie et al. | Imaging of STAT3 signaling pathway during mouse embryonic stem cell differentiation | |
WO2021172542A1 (en) | Mature-cardiomyocyte production method | |
WO2021032271A1 (en) | Induction of functional astrocytes from pluripotent stem cells | |
JP2021048875A (en) | Method for producing pancreatic endocrine cells, and transdifferentiation agent | |
Yada et al. | Rhesus macaque iPSC generation and maintenance | |
US20220169990A1 (en) | Method for producing cardiomyocyte | |
Zhang et al. | High-throughput optical action potential recordings in hiPSC-derived cardiomyocytes with a genetically encoded voltage indicator in the AAVS1 locus | |
Lenka | Derivation and characterization of neural cells from embryonic stem cells using nestin enhancer | |
Ojala et al. | Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells | |
Häcker | In Vitro Generation of Murine Dendritic Cells from Hoxb8-Immortalized Hematopoietic Progenitors | |
WO2023243679A1 (en) | Method for producing high-titer viral vector | |
Liu et al. | Generation and primary characterization of iAM-1, conditionally immortalized atrial myocytes with preserved cardiomyogenic differentiation capacity | |
Laemmle | Polycistronic HSV vectors for the differentiation of embryonic stem cells toward a cardiac lineage | |
CN116790485A (en) | Method for inducing myocardial cells to reprogram into cardiac progenitor cells by using small molecule drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190821 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201013 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230801 |